Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 28, 2017
Pharmacy Choice - News - Generic Drugs - April 28, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 201     Next >>     Go To Page:

4/20/17 - Global $228.8 Billion Generic Drugs Market 2017-2022 - Key Players are Freseunis, Hospira, Mylan, Novartis, Sandoz & Teva Pharmaceuticals - Research and Markets
Research and Markets has announced the addition of the "Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report to their offering. The global generic drugs market was valued at around US$ 228.8 Billion in 2016, growing at a CAGR of around 9% during 2010-2016. The biggest catalyst for growth is a
4/20/17 - Growth Opportunities in the Pharmaceutical PPE Market, 2016
This market insight covers the growth opportunities for personal protective equipment in the pharmaceutical industry. The study addresses key aspects such as market drivers and restraints, key regulations, the impact of policy changes, and the potential for growth for pharmaceutical PPE in key applications. Read the full report:...
4/20/17 - Japan's Sawai Pharmaceutical to Acquire the Generics Business of U.S. Upsher-Smith Laboratories
TOKYO and MINNEAPOLIS, April 20, 2017/ PRNewswire/ Sawai Pharmaceutical Co. Ltd., a leading Japanese generic pharmaceuticals manufacturer, and Upsher-Smith Laboratories, Inc.,, an established generics manufacturer based in Minnesota, U.S., today announced the signing of an agreement for Sawai to purchase the generic pharmaceuticals business of...
4/20/17 - Mylan Launches Generic Trilafon Tablets
HERTFORDSHIRE, England and PITTSBURGH, April 20, 2017/ PRNewswire/ Mylan N.V., today announced the U.S. launch of Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg, a generic version of the reference listed drug, Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg, originally marketed by Schering. Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg, and 16 mg,
4/20/17 - Research and Markets - Global Biosimilar Pipeline and Market Prospects 2017-2022: Focus on Basaglar, Inflectra, Benepali, Rituximab, Trastuzumab, Adalimumab and Bevacizumab
Research and Markets has announced the addition of the "Global Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through Risk Management and Quality by Design" report to their offering. "Global Biosimilar Pipeline and Market Prospects: Overcoming Production Complexities Through Risk Management and Quality by Design"...
4/20/17 - Teva Launches AirDuo? RespiClick and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol
Teva Pharmaceutical Industries Ltd., today announced the simultaneous launch of AirDuo? RespiClick inhalation powder and its authorized generic for the treatment of asthma in patients aged 12 years and older who are uncontrolled on an inhaled corticosteroid or whose disease severity clearly warrants the use of an ICS/long-acting beta 2- adrene
4/20/17 - US Generic Drug Market 2017-2022: Patent Expiry of Blockbuster Drugs, Price Differential between Generics and Innovator Drugs, Incentives for Dispensing and Prescribing Generic Drugs
Dublin- Research and Markets has announced the addition of the "US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report to their offering. The US generic drug market has witnessed a transformation over the last three decades. From less than 20% of the total prescriptions, generic drugs now account fo
4/20/17 - US Generic Drug Market 2017-2022: Patent Expiry of Blockbuster Drugs, Price Differential between Generics and Innovator Drugs, Incentives for Dispensing and Prescribing Generic Drugs - Research and Markets
Research and Markets has announced the addition of the "US Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report to their offering. The US generic drug market has witnessed a transformation over the last three decades. From less than 20% of the total prescriptions, generic drugs now account for the ma
4/20/17 - VANC Pharmaceuticals Appointment of Mr. Alan Arnstein to its Board of Directors
VANC Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter markets is pleased to announce the appointment of Mr. Mr. Arnstein previously worked for the Katz Group Canada where he oversaw the development of the Medicine Shoppe from 28 stores to 175 stores before the successful sale to McKesson Canad
4/19/17 - Actis portfolio company MdiS Group announces the acquisition of Winthrop Pharma Senegal from Sanofi
Actis, a leading growth markets investor, today announced that its portfolio company MdiS, a major pharmaceutical company based in Tunisia, has acquired Winthrop Pharma Senegal from Sanofi. MdiS has more than 720 marketing authorizations worldwide, 480 of which are in Africa, and is constantly expanding its international presence with a subsi
4/19/17 - AG Peterson Urges Eligible Nebraska Residents to Submit Claims for Provigil Settlement
Nebraska Attorney General Doug Peterson issued the following news release:. Attorney General Doug Peterson is urging Nebraska residents to file claims or make their views known on a $125 million multistate settlement that provides $35 million for distribution to consumers who paid for the brand-name drug Provigil or generic modafinil from June 24,
4/19/17 - ANI Pharmaceuticals Announces Launch of Indapamide Tablets
ANI Pharmaceuticals, Inc. today announced launch of Indapamide Tablets, 1.25 mg and 2.5 mg, which is used in the treatment of hypertension and swelling associated with congestive heart failure. Arthur S. Przybyl, ANI's President and CEO stated, "This is the second product that we are launching from the basket of 22 previously marketed generic pro
4/19/17 - Aspen's shares slide on supply allegations [BusinessReport (South Africa)]
Cape Town- Aspen shares fell sharply on Tuesday as the branded and generic pharmaceutical products group moved to water down allegations that it withheld life-saving drugs to drive up prices by 4 000 percent in some of its Spanish market. Aspen shares fell 4.14 percent to close at R268.50 on the JSE, after reports in the UK surfaced about the pharm
4/19/17 - GOVT'S GENERIC PUSH WILL DENT Rs90,000-CRORE BRANDED PHARMA MARKET
The Ministry of Health, Government of India, is amending the Drugs and Cosmetics Act to make it mandatory for doctors in the country to prescribe pure generic drugs and not branded generics as is the practise now. This will impact the branded generics market, which is valued at Rs90, 000 crore. The move is aimed at cutting down the prices of pharma
4/19/17 - Modi govt plan on generic drugs makes pharma companies, doctors jittery [Syrian Arab News Agency]
To make health care affordable in the country, the Narendra Modi-led central government is looking to make it mandatory for doctors to prescribe generic drugs. As reported earlier, the health ministry, in line with Finance Minister Arun Jaitleys Union Budget announcement, has started work on amending the Drugs and Cosmetics Act. After the Act has b
4/19/17 - PM`s push for generic drugs to shift focus to chemists, says pharma industry body [Sport360]
The Indian Pharmaceutical Alliance said that due to the nature of the current off-patent medicines market in India, if such a step were to be followed, the choice of products will be shifted from doctors to chemists, not patients. Elaborating on the challenges, IPA Secretary General told PTI that India is predominantly a market of off-patent medici
4/19/17 - Prescribing generic medicines may commoditise entire pharma industry: Experts [T-break Tech (Middle East)]
To break the nexus between pharmaceutical companies and doctors pushing expensive branded medicines, Prime Minister Narendra Modi yesterday, announced a major step. Kewal Handa, Former MD, Pfizer and Chaturya Aggarwal, Pharma Analyst at IDBI Capital discuss the impact of the above decision on the healthcare and pharma industry. Currently, India has
4/18/17 - Argentum Pharmaceuticals and Allergan Settle Patent Dispute Over RESTASIS
Argentum Pharmaceuticals LLC, a generic pharmaceutical company, announced that it has reached a settlement and license agreement with Allergan, Inc. related to Argentum's generic version of RESTASIS . The agreement generally provides that Argentum may commence marketing its generic equivalent product sometime prior to the expiration of the pate
4/18/17 - Intellipharmaceutics Reports Director Election Results
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reports, as required by TSX rules, that the six nominees, each of whom was an incumbent director of the Company, identified in the Managem
4/18/17 - Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that it has appointed Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance.. Mr. DiPaolo has extensive experience in the pharmaceutical industry, both...
4/18/17 - MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
MATINAS BIOPHARMA HOLDINGS, INC. (OTCMKTS:MTNB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Cert
4/18/17 - MATINAS BIOPHARMA HOLDINGS, INC. FILES (8-K) Disclosing Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits
Previously from October 2015 until April 2017, Mr. DiPaolo served as Senior Vice President of Quality, Compliance and Regulatory Affairs at Cyalume Technologies Holdings, Inc., a diversified pharmaceutical and medical device company. Prior to Cyalume, from August 2011 until July 2015, Mr. DiPaolo served as Senior Vice President, Quality, Compliance
4/18/17 - Oncobiologics Secures Additional Funding [Syrian Arab News Agency]
-Oncobiologics, Inc., a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody biosimilar therapeutics, today announced that it has amended its Note and Warrant Purchase Agreement dated December 22, 2016 and issued additional senior secured promissory notes that...
4/18/17 - PM Narendra Modi hints at rules for doctors to prescribe generic drugs [Sudan Tribune]
Prime Minister Narendra Modi today indicated that his government may bring in a legal framework under which doctors will have to prescribe generic medicines, which are cheaper than equivalent branded drugs, to patients. Modi said his government brought in a health policy after 15 years and capped the prices of medicines and stents, which has angere
4/18/17 - Research Reports Coverage on Generic Drugs Stocks Innocoll, Catalyst Pharma, Galectin Therapeutics, and Tetraphase Pharma
Under assessment this morning are: Innocoll Holdings PLC, Catalyst Pharmaceuticals Inc., Galectin Therapeutics Inc., and Tetraphase Pharmaceuticals Inc.. Athlone, Ireland headquartered Innocoll Holdings PLC's stock finished Monday's session 0.25% lower at $1.99 with a total trading volume of 379,422 shares. Moreover, shares of Innocoll Holdings, wh
Articles(s): 1 - 25 of 201     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415